Clinical trials: Macular Pigmentation
Macular Degeneration, Retinal Detachment
A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes
The purpose of this study is to determine treatment effects in patients with retinal pigment epithelium detachment (PED) in relation to Age Related Maculopathy (AMD).
- Trial name
- NCT01746875
- Testing
- Aflibercept, Verteporfin
- Where
- Norway
- Volunteers
- 9 people
- Sponsor
- Norwegian University of Science and Technology
Age Related Macular Degeneration
Retinal Pigment Epithelium Safety Study for Patients in B4711001
This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety.
- Trial name
- NCT03102138
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Age Related Macular Degeneration
FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment
To investigate the effects of lutein supplementation on macular pigment density using FLIO and MPOD measurements in patients with age-related macular degeneration and healthy subjects over a course of 6 months.
- Trial name
- FLOS (NCT04761341)
- Testing
- NUTROF TOTAL
- Where
- Switzerland
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration
The investigators hypothesize that it is safe and effective to treat patients with choroidal neovascularisation (abnormal blood vessels growing under the retina) secondary to causes other than age related macular degeneration…
- Trial name
- NCT01628354
- Testing
- Ranibizumab
- Where
- Australia
- Volunteers
- 49 people
- Sponsor
- University of Melbourne
Pigment Epithelial Detachment
Lucentis to Treat Pigment Epithelial Detachment
Patients with Pigment Epithelial Detachments secondary to Age-Related Macular Degeneration (AMD) will receive intravitreal Lucentis monthly for 6 months in the hope of improving visual acuity from a baseline evaluation.
- Trial name
- NCT00841581
- Testing
- Ranibizumab
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Primary Intestinal Hypocholesterolemia, Abetalipoproteinemia
CArotenoid in hypoChOlesterolemia
Hypobetalipoproteinemias (HBL) represent a heterogeneous group of disorders characterized by reduced plasma levels of plasmatic lipids (mainly triglycerides, total cholesterol (TC), LDL-cholesterol (LDL-C), and apolipoprotein B…
- Conditions
- Primary Intestinal Hypocholesterolemia, Abetalipoproteinemia, Chylomicron Retention Disease
- Trial name
- CaCo (NCT05208879)
- Testing
- Characterization of carotenoid status and plasma levels of oxidative stress markers in patients (case group only), Characterization, evaluation and comparison of macular pigment density
- Where
- 3 sites in France
- Volunteers
- 10 people
- Sponsor
- Hospices Civils de Lyon
Dry Age-related Macular Degeneration
Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells
This project intends to transplant human embryonic stem cells derived retinal pigment epitheliums into subretinal space of patients to treat dry age-related macular degeneration(dry-AMD).And we will assess the safety and efficacy…
- Trial name
- NCT03046407
- Testing
- retinal pigment epithelium transplantation
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chinese Academy of Sciences
Geographic Atrophy, Age-related Macular Degeneration
Micropulse Laser for Geographic Atrophy
Geographic atrophy (GA) causes the loss of the retinal pigment epithelium (RPE) cells in broad areas of the retina. The application of subthreshold micropulse laser spots in healthy RPE in the vicinity of the area of GA may…
- Trial name
- MPL4DRY (NCT01799564)
- Testing
- Micropulse
- Where
- Spain
- Volunteers
- 11 people
- Sponsor
- Institut de la Macula y la Retina
Age Related Macular Degeneration
Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)
The investigators hope to determine if "wet" AMD patients differ from patients with "dry" AMD or normal eyes in the production of anti-retinal pigment epithelium (anti-RPE) or anti-retinal antibody formation.
- Trial name
- Antibody (NCT00931489)
- Testing
- ranibizumab (Lucentis(R))
- Where
- United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Lawrence S. Morse, MD
Age-Related Macular Degeneration, Diabetic Maculopathy
Selective RPE Laser Treatment (SRT) for Various Macular Diseases
In this prospective clinical study SRT is performed with various pulse durations at 1.7µs and additionally 200ns to evaluate the different clinical effects of both laser regimens.
- Conditions
- Age-Related Macular Degeneration, Diabetic Maculopathy, Central Serous Chorioretinopathy
- Trial name
- NCT00403884
- Testing
- Selective RPE laser treatment
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Regensburg
Atrophy, Geographic Atrophy
Sparing of the Fovea in Geographic Atrophy Progression
Dry age-related macular degeneration (AMD) is a common cause for severe visual loss in the elderly and represents an unmet need.
- Conditions
- Atrophy, Geographic Atrophy, Age-related Macular Degeneration, Eye Diseases
- Trial name
- SIGHT (NCT02332343)
- Testing
- No intervention - Natural history study
- Where
- Germany
- Volunteers
- 26 people
- Sponsor
- University Hospital, Bonn
Age-Related Macular Degeneration
Triamcinolone Acetonide in Patients With Serous Pigment Epithelial Detachment
The purpose of this study is to determine the effectiveness and safety of triamcinolone acetonide in patients with serous pigment detachment associated with age-related macular degeneration
- Trial name
- COAST_UA_AMD (NCT04292756)
- Testing
- Subtenon injection of 40 mg triamcinolone acetonide, Intravitreal injection of 4 mg triamcinolone acetonide, Visometry
- Where
- 4 sites in Ukraine
- Volunteers
- 63 people
- Sponsor
- The Filatov Institute of Eye Diseases and Tissue Therapy
Posterior Capsule Opacification, Retinal Degeneration
Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification
It has been hypothesized that potential effects of laser Nd: YAG laser posterior capsulotomy may affect macular pigment as well as choroidal thickness, macular thickness and anterior chamber parameters, so it was aimed to…
- Conditions
- Posterior Capsule Opacification, Retinal Degeneration, Retinal Detachment, Anterior Chamber Angle Congestion
- Trial name
- NCT03321253
- Testing
- Nd: YAG laser posterior capsulotomy
- Volunteers
- 38 people
- Sponsor
- Afyon Kocatepe University Hospital
Macular Pigment Optical Density
Wenzhou Dry Age-related Macular Degeneration (AMD) Progression Study
To evaluate the correlation between macular pigment optical density (MPOD) levels and risk of progression in patients with age-related macular degeneration
- Trial name
- NCT03433885
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Eye Hospital of Wenzhou Medical University
Wet Macular Degeneration, Macular Degeneration
HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
In this fifth year of anti-VEGF therapy for neovascular AMD, retinal physicians are collecting groups of patients who either do not or only partially respond to anti-VEGF therapy.
- Conditions
- Wet Macular Degeneration, Macular Degeneration, Retinal Pigment Epithelial Detachment
- Trial name
- HiPED (NCT01189019)
- Testing
- ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Anne Fung MD
AMD
Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation
Background: Age-related macular degeneration (AMD) is an eye disease. It is the leading cause of vision loss in people over 55 in the U.S. Changes in the eye can make it difficult for the eye to adjust to low light.
- Trial name
- NCT03478865
- Testing
- Vitamin A palmitate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Eye Institute (NEI)
Glaucoma
Macular Pigment and Visual Performance in Glaucoma Patients
The purpose of this study is to determine cross-sectional relationships between macular pigment optical density (MPOD) and visual performance in glaucoma.
- Trial name
- NCT03959592
- Testing
- Lutein, zeaxanthin and mesozeaxanthin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Felipe Medeiros, MD
Retinal Pigment Epithelial Detachment With Vascularization, Age Related Macular Degeneration
Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration
This is a pilot, single-center, interventional clinical trial in which subjects will receive 16 Gy of IRay treatment and Lucentis, followed by Lucentis treatment as needed.
- Trial name
- NCT01521819
- Testing
- Iray, Lucentis
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Oraya Therapeutics, Inc.
Degenerative Myopia With Macular Hole
Clinical Research of Human Retinal Pigment Epithelial (HuRPE) Cell Injection on Atrophy of High Myopia Macular Area
To evaluate the safety and tolerability of human retinal pigment epithelial (HuRPE) cell injection subretinal transplantation for atrophy of high myopia macular area, and to explore the maximum tolerated dose (MTD).
- Trial name
- NCT04212624
- Testing
- Human retinal pigment epithelial (HuRPE) cell injection
- Volunteers
- 9 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Macular Degeneration, Wet Macular Degeneration
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis.
- Conditions
- Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration, Retinal Diseases
- Trial name
- ARI2 (NCT02157077)
- Testing
- Aflibercept
- Where
- 9 sites in France
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil